Molecular monitoring of human immunodeficiency virus type 1 infection. 1997

M Clementi, and P Bagnarelli, and S Menzo, and M Cardelli, and F Mazzola, and R Sampaolesi
Dipartimento di Scienze Biomediche, Università di Trieste, Italy.

Over the past few years, considerable technical effort has been directed to developing molecular methods that would allow an effective approach to the diagnosis of human immunodeficiency virus type 1 (HIV-1) infection and its monitoring. Indeed, quantitative molecular techniques have opened the way for a new type of direct study of untreated and treated HIV-1 infected subjects. The understanding of the immunopathogenesis of HIV-1 infection has increased significantly with the introduction of advanced virological and molecular methods for accurate quantitative analysis of HIV-1 activity; powerful methodologies answer (directly and in real time) most questions generated by pathogenic research and by the novel anti-viral strategies introduced in clinical practice. The data from pilot diagnostic applications of quantitative techniques have clarified important features of the natural history of HIV-1 infection. Moreover, an increasing amount of data indicate the need for second-level laboratory facilities for the clinical management of infected patients; virological aspects and some genetic features of the hosts concerning HIV-1 co-receptors (all the co-receptors so far identified are members of, or related to, the transmembrane, chemokine-receptor family) need to be elucidated for the complete diagnostic evaluation of HIV-1-infected subjects.

UI MeSH Term Description Entries
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000956 Antigens, Viral Substances elaborated by viruses that have antigenic activity. Viral Antigen,Viral Antigens,Antigen, Viral
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human

Related Publications

M Clementi, and P Bagnarelli, and S Menzo, and M Cardelli, and F Mazzola, and R Sampaolesi
January 1991, The New England journal of medicine,
M Clementi, and P Bagnarelli, and S Menzo, and M Cardelli, and F Mazzola, and R Sampaolesi
June 2005, Current HIV/AIDS reports,
M Clementi, and P Bagnarelli, and S Menzo, and M Cardelli, and F Mazzola, and R Sampaolesi
July 1998, The New England journal of medicine,
M Clementi, and P Bagnarelli, and S Menzo, and M Cardelli, and F Mazzola, and R Sampaolesi
September 2002, Journal of virology,
M Clementi, and P Bagnarelli, and S Menzo, and M Cardelli, and F Mazzola, and R Sampaolesi
September 1996, Transfusion science,
M Clementi, and P Bagnarelli, and S Menzo, and M Cardelli, and F Mazzola, and R Sampaolesi
September 2000, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi,
M Clementi, and P Bagnarelli, and S Menzo, and M Cardelli, and F Mazzola, and R Sampaolesi
November 1988, Presse medicale (Paris, France : 1983),
M Clementi, and P Bagnarelli, and S Menzo, and M Cardelli, and F Mazzola, and R Sampaolesi
January 1995, Annales de dermatologie et de venereologie,
M Clementi, and P Bagnarelli, and S Menzo, and M Cardelli, and F Mazzola, and R Sampaolesi
November 2017, Biochemical and biophysical research communications,
M Clementi, and P Bagnarelli, and S Menzo, and M Cardelli, and F Mazzola, and R Sampaolesi
October 2022, Infectious diseases & immunity,
Copied contents to your clipboard!